Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age25+
SponsorM.D. Anderson Cancer Center

About this trial

To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants must have one of the following histology documented tumor types: non-small cell lung carcinoma, renal cell carcinoma, urothelial carcinoma, prostate cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer, gastric/GEJ cancer, cervical, anal, or MSI-high

Documentation of locally advanced, recurrent, or metastatic incurable malignancy that has partially responded or progressed after at least 1 available standard therapy and disease is stable (no progression of disease for 3 months or more on current treatment regimen)

No prior grade 3 AEs on current standard of care cancer treatment regimen;

Age ≥ 25 years; as by the age of 25 brain is fully developed.

Disqualifiers

History of depression prior to cancer diagnosis.

History of bipolar disorder, psychosis (of any nature), and seizures.

Functionally limiting comorbid conditions such as second primary malignancies in CNS or chest, and history of total laryngectomy or total .glossectomy.

ECG with QTc > 450.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Psilocybin

    Drug

    Given by PO

  • Niacin

    Other intervention

    Given by PO

Treatment groups

48 Participants
are divided into 2 treatment groups
Group A: Arm AExperimental treatment 1 intervention
Group B: Arm BPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Safety and adverse events (AEs)

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Time frame
Through study completion; an average of 1 year.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

M.D. Anderson Cancer Center

Lead sponsor

Gateway for Cancer Research

Collaborator